Free Trial

JPMorgan Chase & Co. Lowers Holdings in Nu Skin Enterprises, Inc. $NUS

Nu Skin Enterprises logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan Chase & Co. reduced its stake in Nu Skin by 35.6% in Q3, selling 271,970 shares and leaving it with 492,082 shares (about 1.01% of the company) worth roughly $5.998 million.
  • Recent results missed expectations: Nu Skin reported EPS of $0.29 versus $0.30 expected and revenue of $370.3M versus $382.7M, while trading at a low valuation (market cap ≈ $350.7M, P/E 2.28).
  • The company pays a $0.06 quarterly dividend (about a 3.3% yield), but analyst sentiment has weakened to a consensus "Reduce" after recent downgrades.
  • MarketBeat previews top five stocks to own in May.

JPMorgan Chase & Co. lowered its holdings in Nu Skin Enterprises, Inc. (NYSE:NUS - Free Report) by 35.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 492,082 shares of the company's stock after selling 271,970 shares during the quarter. JPMorgan Chase & Co. owned 1.01% of Nu Skin Enterprises worth $5,998,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Coldstream Capital Management Inc. purchased a new stake in Nu Skin Enterprises in the 3rd quarter valued at about $181,000. XTX Topco Ltd boosted its stake in Nu Skin Enterprises by 3.9% during the third quarter. XTX Topco Ltd now owns 89,314 shares of the company's stock worth $1,089,000 after buying an additional 3,314 shares during the period. Wexford Capital LP purchased a new position in Nu Skin Enterprises during the third quarter worth about $40,000. Polymer Capital Management US LLC purchased a new position in Nu Skin Enterprises during the third quarter worth about $258,000. Finally, Mariner LLC increased its position in shares of Nu Skin Enterprises by 52.0% during the third quarter. Mariner LLC now owns 27,808 shares of the company's stock valued at $339,000 after acquiring an additional 9,517 shares during the last quarter. Institutional investors and hedge funds own 82.84% of the company's stock.

Nu Skin Enterprises Stock Performance

NYSE NUS opened at $7.29 on Wednesday. The company has a market cap of $350.68 million, a P/E ratio of 2.28 and a beta of 1.05. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.08 and a quick ratio of 1.40. The stock has a 50-day moving average of $8.68 and a two-hundred day moving average of $9.93. Nu Skin Enterprises, Inc. has a 1-year low of $5.32 and a 1-year high of $14.62.

Nu Skin Enterprises (NYSE:NUS - Get Free Report) last issued its quarterly earnings results on Friday, February 13th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by ($0.01). Nu Skin Enterprises had a return on equity of 8.14% and a net margin of 10.79%.The business had revenue of $370.32 million for the quarter, compared to analyst estimates of $382.70 million. As a group, analysts anticipate that Nu Skin Enterprises, Inc. will post 1.05 EPS for the current year.

Nu Skin Enterprises Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 11th. Shareholders of record on Friday, February 27th were given a $0.06 dividend. This represents a $0.24 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Friday, February 27th. Nu Skin Enterprises's dividend payout ratio (DPR) is currently 7.50%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NUS. Wall Street Zen downgraded shares of Nu Skin Enterprises from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Zacks Research cut shares of Nu Skin Enterprises from a "hold" rating to a "strong sell" rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Nu Skin Enterprises in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Reduce".

Check Out Our Latest Stock Report on Nu Skin Enterprises

About Nu Skin Enterprises

(Free Report)

Nu Skin Enterprises, Inc is a Utah-based direct selling company that develops and distributes personal care products and dietary supplements. Operating through a network marketing model, Nu Skin offers a portfolio of wellness, anti-aging skin care, hair care and nutritional products designed to support healthy living and appearance. The company leverages independent distributors to market its offerings directly to consumers across multiple channels, including online platforms and localized events.

Founded in 1984 by Blake M.

Featured Articles

Institutional Ownership by Quarter for Nu Skin Enterprises (NYSE:NUS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nu Skin Enterprises Right Now?

Before you consider Nu Skin Enterprises, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nu Skin Enterprises wasn't on the list.

While Nu Skin Enterprises currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines